The heterocyclic building block 3-(1-Piperazinyl)-1,2-Benzisothiazole (CAS 87691-88-1; empirical formula C₁₁H₁₃N₃S; molecular weight 219.31 g/mol) is supplied as a white to off-white crystalline powder with a melting range typically observed between 89°C and 93°C by differential scanning calorimetry (DSC) at a ramp rate of 10 K/min. Commercially available lots intended for pharmaceutical intermediate use are routinely controlled to an HPLC purity of ≥ 98.0% (area normalization, detection at 254 nm), with single impurities capped at ≤ 0.5% and total impurities not exceeding 2.0%. The product is classified under Harmonized System code 2934.99 and is shipped under ambient conditions in double polyethylene-lined fibre drums, with a retest date assigned at 24 months when stored below 25°C in a desiccated environment. Its core structural motif—a 1,2-benzisothiazole ring bearing a piperazine substituent at the 3-position—places it at the confluence of heterocyclic chemistry and central nervous system (CNS) drug substance synthesis, most notably as the penultimate intermediate in the industrial preparation of the atypical antipsychotic ziprasidone hydrochloride monohydrate.
Throughout pilot-plant campaigns utilizing a 1000 L glass-lined reactor train, charge control of the piperazine moiety has repeatedly proven critical. Under typical basic conditions (aqueous Na₂CO₃, pH 9.0–9.5), the N-1 nitrogen of the piperazine ring exhibits a nucleophilic displacement reactivity profile toward 3-chloro-1,2-benzisothiazole that is subject to competing hydrolysis if the water content exceeds 5% v/v. Batch records from kilo-lab runs indicate that pre-drying of the 1,2-benzisothiazole precursor over molecular sieves (type 3A) for 12 hours suppresses the generation of the 3-hydroxybenzisothiazole impurity to below 0.15%, avoiding a downstream palladium-scavenging step that would otherwise be required to meet ICH Q3A thresholds.
What Limits the Utility of Unsubstituted 1,2-Benzisothiazole in CNS Candidate Synthesis?
A direct comparison between the piperazinyl-substituted molecule and the parent 1,2-benzisothiazole (CAS 272-16-2) reveals a divergence in both electronic landscape and pharmacokinetic liability. The unsubstituted heterocycle, while serving as a bioisostere of indole, suffers from deficient basicity (conjugate acid pKₐ ≈ −0.5) that precludes the formation of a stable salt suitable for oral dosage forms. Introduction of the piperazine ring at the 3-position raises the pKₐ of the most basic nitrogen to approximately 8.4, enabling hydrochloride salt formation in a mixed isopropanol/water antisolvent crystallization system operated at a jacket temperature of 0°C to 5°C. This single modification transforms a neutral, poorly soluble scaffold into a salt-forming intermediate that can be progressed to a final drug substance without introducing a separate salt-forming step late in the synthesis. The difference extends to solubility profiles: while 1,2-benzisothiazole exhibits an aqueous solubility below 0.1 mg/mL at 25°C, the hydrochloride salt of the piperazinyl derivative exceeds 5 mg/mL in purified water, facilitating aqueous work-up during the final coupling to the chloroalkylindoline fragment.
In impurity reference standard programs governed by the European Pharmacopoeia (Ph. Eur.) monograph 01/2017:2740 for ziprasidone hydrochloride, this compound is formally catalogued as Ziprasidone Related Compound A. Its use as a system suitability marker in the official HPLC method (column: octadecylsilyl silica gel, 5 µm, 250 mm × 4.6 mm; mobile phase: methanol, buffer solution pH 6.5; flow rate 1.0 mL/min; detection 254 nm) demands a certified purity assignment against a secondary reference standard traceable to a primary standard characterized by quantitative NMR (qNMR) using maleic acid as internal calibrant. Differences between supplier lots arise primarily in the residual ethanol content—typically ≤ 3000 ppm by headspace GC-FID—and in the polymorphic form, with Form I (melting endotherm 90.2°C) being thermodynamically preferred over Form II (87.5°C) at room temperature.
Specifications for material destined for cGMP intermediate campaigns align with a multi-tiered release testing protocol. The following data, drawn from a composite of certificate-of-analysis summaries, illustrates the typical numeric boundaries enforced at the quality control laboratory.
| Parameter | Acceptance Criterion | Typical Observed Value | Analytical Procedure |
|---|---|---|---|
| Appearance | White to off-white powder | Conforms | Visual inspection under D65 illumination |
| Assay (anhydrous basis) | 98.0%–102.0% | 99.2% | HPLC, area%, 254 nm, per in-house method TM-0421 |
| Water content | ≤ 0.5% | 0.12% | Karl Fischer coulometry, oven method 150°C |
| Residue on ignition | ≤ 0.1% | 0.03% | Ph. Eur. 2.4.16, 600°C |
| Heavy metals (as Pb) | ≤ 20 ppm | < 10 ppm | ICP-MS, per USP <232> |
| Benzisothiazole dimer | ≤ 0.15% | 0.04% | Gradient HPLC, RRT 1.37 |
Impurity Fate Mapping During Reductive Amination and Final Coupling
A process-scale differentiating factor between this intermediate and the analogous 3-(piperazin-1-yl)benzo[d]isothiazole isomers (e.g., the 2,1-benzisothiazole regioisomer) surfaces during the reductive amination step in ziprasidone manufacture. When the piperazinyl nitrogen undergoes Schiff base formation with a substituted acetaldehyde derivative, the 1,2-benzisothiazole sulfur atom exerts a through-space electron-withdrawing effect that lowers the imine formation equilibrium constant compared to the 2,1-isomer. This necessitates a larger molar excess (1.5–2.0 equivalents) of the aldehyde component and extended aging at 20°C for 8 hours to achieve a conversion exceeding 95%. Quenching with sodium triacetoxyborohydride (STAB, 1.3 eq.) in dichloromethane yields the tertiary amine intermediate with less than 0.20% residual secondary amine when the reaction mixture is maintained at pH 4.5–5.5 via acetic acid addition. Pilot-plant deviations from this pH window have produced N-oxide side-products exceeding 1.0%, requiring a labor-intensive silica gel chromatography polish step. These kinetic constraints are not observed with 4-(1-piperazinyl)quinoline or similar heteroaryl-piperazine systems, where the electron density at the reacting nitrogen is less attenuated.
The compound also serves as a key starting material for structure-activity relationship (SAR) libraries exploring dual 5-HT1A/5-HT2A receptor antagonists. In such campaigns, the free base is dissolved in anhydrous DMF and treated with various alkyl halides in the presence of potassium carbonate (325 mesh, 2.5 eq.) and a catalytic amount of sodium iodide. Typical reaction monitoring by TLC (silica gel 60 F₂₅₄, eluent: ethyl acetate/hexane 1:1 v/v) indicates completion within 4 hours at 60°C. The absence of a protecting group requirement at the piperazine N-4 position—a workflow advantage over piperazine itself, which frequently requires Boc protection—stems from the pronounced nucleophilicity differential between N-alkyl and N-aryl nitrogens in the fused benzisothiazole system.
Vendors supplying the compound under research-grade and cGMP intermediate classifications include Toronto Research Chemicals (catalogue prefix TRC-P479500), TCI America, and Sigma-Aldrich. Lot-specific differences are most often encountered in the content of the 3-methoxybenzisothiazole impurity, a carryover from the initial 3-chlorination step using phosphorus oxychloride in the presence of residual methanol. Tightly controlled lots from cGMP facilities specify this impurity at ≤ 0.10%, monitored by LC-MS single-ion recording at m/z 207.2.
When the Chromophore Conditions Limit UV Quantitation: The Case for Charged Aerosol Detection
In method development laboratories tasked with purity assignment of early-stage intermediates, the low specific absorbance of the benzisothiazole nucleus at wavelengths above 230 nm can introduce a relative response factor (RRF) bias approaching 15% for related substances lacking the piperazine substituent. A growing number of contract manufacturing organizations have migrated quantitation to a charged aerosol detector (CAD) platform, coupling it with a phenyl-hexyl stationary phase (3 µm, 150 mm × 3.0 mm) and a gradient of acetonitrile in 10 mM ammonium formate buffer (pH 4.0). This system generates a linear response between 0.05% and 120% of the nominal concentration without the need for individual impurity reference standards, a critical advantage during process development when the impurity profile is not yet fully characterized. The CAD method yields a limit of quantitation (LOQ) of 0.03%, fully compliant with ICH Q3A reporting threshold for a maximum daily dose of ziprasidone up to 200 mg.
| Feature | 3-(1-Piperazinyl)-1,2-Benzisothiazole | 3-Chloro-1,2-Benzisothiazole | 1-(1,2-Benzisothiazol-3-yl)piperazine-4-carboxylic acid tert-butyl ester |
|---|---|---|---|
| Role in ziprasidone route | Penultimate intermediate, direct coupling partner | Electrophilic precursor to piperazine displacement | Protected intermediate requiring deprotection before use |
| Process safety concern | Dust generation; respiratory sensitization potential | Skin corrosion (Category 1B); H314 | Teratogenicity alert from in silico DEREK analysis; low mutagenicity in Ames test |
| Typical batch purity target | > 99.0% (cGMP) | > 97.0% (technical grade used with purification) | > 98.5%; Boc deprotection generates isobutylene off-gas, requiring scrubbed vent |
| Storage condition | Ambient, desiccated, ≤ 25°C | 2–8°C, under nitrogen | −20°C, argon blanket |
For contract development and manufacturing organizations (CDMOs) qualifying new suppliers, the failure mode most frequently encountered is a higher-than-specified content of the symmetrical urea dimer formed by phosgene carryover from the chloro-benzisothiazole synthesis. Detection of this impurity at levels exceeding 0.15% by UPLC-QTOF necessitates a supplier corrective action that replaces the phosgene-based chlorination with a phosphorus oxychloride/phosphorus pentachloride mixture, reducing the urea dimer burden to below 0.05%. Published data for the exact long-term photostability of this intermediate under ICH Q1B conditions is limited; however, forced degradation studies indicate that exposure to UV-A light (peak 365 nm) for 24 hours in the solid state produces a 0.2% increase in an unknown photodegradant (RRT 0.71) that was subsequently identified by preparative LC-NMR as a sulfoxide derivative. Consequently, packaging in opaque HDPE containers with a light-protective secondary overwrap is now stipulated in quality agreements for shipment to sites lacking amber-glass-lined storage vessels.
